0REN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High ProfitabilityEdwards' persistently high gross and operating margins reflect durable pricing power in premium structural heart devices and efficient cost structure. High margins provide long-term cash generation capacity, funding R&D, buybacks, and cushioning against cyclical procedure volumes.
Conservative Balance SheetVery low leverage gives the company flexibility to invest in innovation, execute buybacks, and withstand reimbursement or procedure-volume shocks. Strong equity base and mid-teens free cash support capital allocation without jeopardizing liquidity or credit profile over the medium term.
Structural Product GrowthRapid TMTT adoption plus steady TAVR growth and clinical/regulatory wins (new devices, CE/approvals, durability data) expand addressable market. A diversified platform across TAVR, mitral, tricuspid and surgical products supports multi-year procedural and consumable-driven revenue growth.
Bears Say
Weaker Cash ConversionWhile still generating positive free cash flow, the deterioration versus the prior year signals variability in converting earnings to cash. Persistent weaker cash conversion could constrain discretionary spend, slow deleveraging or limit reinvestment if the trend persists.
Subdued Revenue TrendLonger-term top-line growth has been inconsistent, with prior-year volatility and low single-digit TTM expansion. Reliance on procedure volumes and timing of new-indication adoption makes revenue less predictable, challenging steady margin and cash-flow improvement targets.
Regulatory & Trial Timing RiskKey policy decisions and trial readouts drive access and broader adoption. Delays or unfavorable outcomes in CMS coverage reconsideration or PROGRESS could slow U.S. uptake and postpone revenue contributions from expanded indications, creating multi-month timing risk to growth trajectories.
Edwards Lifesciences News
0REN FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Currently, no data Available
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is CHF40.08B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Oct 28, 2026 which is in 85 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Jul 23, 2026. The company reported CHF0.632 earnings per share for the quarter, beating the consensus estimate of CHF0.602 by CHF0.03.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.6.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 575,800,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of CHF0.632 in its last earnings report, beating expectations of CHF0.602. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in GB:0REN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
0REN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted robust top-line growth led by TMTT (+44.8% YoY) and solid TAVR performance (+10.5% YoY), along with margin expansion and upgraded full-year company and segment guidance. Notable clinical and regulatory milestones (SAPIEN X4S, PROGRESS timeline, PASCAL and M3 approvals/CE Mark, COMMENCE 10-year data) underpin multi-year growth prospects. Offsetting factors include foreign exchange headwinds, higher effective tax rate and GAAP earnings impacts from R&D credit changes, higher SG&A, and tougher second-half comparables creating near-term seasonality and uncertainty. On balance, positive execution, upgraded guidance and strong pipeline/clinical evidence outweigh the near-term financial and macro headwinds.View all GB:0REN earnings summaries0REN Net sales Breakdown
73.96% Transcatheter Aortic Valve Replacement
9.07% Transcatheter Mitral and Tricuspid Therapies
16.96% Surgical Structural Heart
